AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.71
+2.50%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.56
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.83
- EPS estimate
- -$0.58
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +1.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $42
- PT range
- $30 – $58
- Analysts
- 5
5 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.58 | -$0.83 | Miss -42.43% | — |
| May 13, 2026 | -$1.00 | -$0.98 | Beat 2.00% | — |
| Mar 23, 2026 | -$1.54 | -$0.37 | Beat 75.97% | $59.0K |
| Nov 6, 2025 | -$1.67 | -$2.19 | Miss -31.14% | — |
| Aug 7, 2025 | -$1.43 | -$1.92 | Miss -34.27% | — |
| Mar 20, 2025 | -$0.39 | -$7.95 | Miss -1938.46% | $192.0K |
| Nov 7, 2024 | -$1.19 | -$2.83 | Miss -137.82% | $249.0K |
| Mar 29, 2024 | -$4.80 | -$116 | Miss -2321.04% | $571.0K |
| Nov 9, 2023 | -$262 | -$26 | Beat 90.00% | $236.0K |
| Aug 3, 2023 | -$214 | -$140 | Beat 34.44% | $643.0K |
| May 4, 2023 | -$231 | -$202 | Beat 12.37% | $475.0K |
| Aug 4, 2022 | -$429 | -$329 | Beat 23.33% | $1.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026